Systemic Dendrimer-Peptide Therapies for Wet Age-Related Macular Degeneration
Wet age-related macular degeneration (AMD) is an end-stage event in a complex pathogenesis of macular degeneration, involving the abnormal growth of blood vessels at the retinal pigment epithelium driven by vascular endothelial growth factor (VEGF). Current therapies seek to interrupt VEGF signaling...
Saved in:
Main Authors: | Tony Wu (Author), Chang Liu (Author), Rangaramanujam M. Kannan (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CRISPR‐based gene therapy for wet age‐related macular degeneration in mouse model
by: Dongchun Xie, et al.
Published: (2024) -
Effect of conbercept or ranibizumab in the treatment of wet age-related macular degeneration
by: Dawei Zhang, et al.
Published: (2019) -
Polymorphic nanobody crystals as long‐acting intravitreal therapy for wet age‐related macular degeneration
by: Shuqian Zhu, et al.
Published: (2023) -
Spotlight on Faricimab in the Treatment of Wet Age-Related Macular Degeneration: Design, Development and Place in Therapy
by: Nair AA, et al.
Published: (2022) -
Profile of ranibizumab: efficacy and safety for the treatment of wet age-related macular degeneration
by: Chen Y, et al.
Published: (2012)